Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11561765 | 0.85 | MMP9 (0.35) | MEN1KMT2A | |
| Cyclobarbital SCHEMBL157224 | 0.69 | MEN1 (0.44) | MEN1KMT2AALDH1A1HCAR2 | |
| SCHEMBL6246587 | 0.69 | GRIN2D (0.35) | MEN1KMT2AALDH1A1HCAR2 | |
| Cyclobarbital SCHEMBL5458050 | 0.69 | HCAR2 (0.40) | MEN1KMT2AHCAR2 | |
| Cyclobarbital SCHEMBL7617865 | 0.69 | MEN1 (0.31) | MEN1KMT2A | |
| Cyclobarbital SCHEMBL1256543 | 0.68 | MEN1 (0.43) | MEN1KMT2AALDH1A1HCAR2 | |
| Heptabarbital SCHEMBL713359 | 0.68 | MEN1 (0.43) | MEN1KMT2AALDH1A1HCAR2 | |
| SCHEMBL437249 | 0.67 | MEN1 (0.35) | MEN1KMT2AALDH1A1 | |
| Cyclobarbital SCHEMBL7698655 | 0.67 | MEN1 (0.42) | MEN1KMT2AHCAR2 | |
| SCHEMBL4530091 | 0.65 | KMT2A (0.50) | MEN1KMT2AALDH1A1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186075-A1 | High-energy cyclodextrin complexes | LOFTSSON THORSTEINN (IS) | 2004-09-23 | — | — | US | disclosed |
| US-6699849-B1 | BIOAVAILABILITY | CYCLOPS, EHF. (IS) | 2004-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186075-A1 | High-energy cyclodextrin complexes | GYS2, SI, GYS1 | MEN1 3887/4885KMT2A 4743/4885ALDH1A1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.